Marksans Pharma has entered into a definitive agreement to acquire 100% of the share capital of QliniQ B.V., a profitable Netherlands-based pharmaceutical company with established sales, marketing and distribution capabilities across the Dutch healthcare market.

The acquisition marks a strategic step in expanding Marksans’ footprint across regulated European markets and advancing its forward-integration strategy through direct, owned market-access capabilities within the European Union. 

QliniQ operates a differentiated portfolio of niche pharmaceuticals and medical devices, with established positions in women’s health, dermatology, respiratory care and other specialty therapeutic categories. 

The company has built long-standing relationships with wholesalers, pharmacies, hospitals and insurer-led tender channels across the Netherlands, providing a strong platform for sustainable growth and market access. 

For the financial year ended December 31, 2025, QliniQ reported revenue of €9.35 million and net profit of €1.01 million. The company achieved a revenue CAGR of approximately 41% between FY2023 and FY2025 while maintaining a debt-free balance sheet. 

Albert de Bruin and Raymond Lansink, Board Members and Shareholders of QliniQ B.V., said that Marksans’ strong product development capabilities, expanding portfolio and high-quality manufacturing expertise make it an ideal partner for the next phase of growth. 

Mark Saldanha, Chairman and Managing Director of Marksans Pharma, said, “This acquisition represents an important strategic step in expanding Marksans’ presence across regulated European markets. It provides Marksans with direct access to the Netherlands market and enhances our ability to commercialize existing and future products across regulated European markets.”